Platform-based analytical approaches are crucial to de-risking and accelerating bioconjugate and antibody-drug conjugate (ADC) development. Because these complex therapeutics combine antibodies, linkers, and payloads, they present a much broader analytical burden than traditional biologics.
By adopting a shared analytical framework, development teams can leverage established method data, run early feasibility assessments, and bypass repetitive assay development. This platform-driven continuity seamlessly bridges the gap between early R&D and GMP manufacturing, supporting smoother scale-up and tighter product control.
Read the full article in BioPharm International to explore our platform analytical strategies.
Platform-based analytical approaches are crucial to de-risking and accelerating bioconjugate and antibody-drug conjugate (ADC) development. Because these complex therapeutics combine antibodies, linkers, and payloads, they present a much broader analytical burden than traditional biologics.
By adopting a shared analytical framework, development teams can leverage established method data, run early feasibility assessments, and bypass repetitive assay development. This platform-driven continuity seamlessly bridges the gap between early R&D and GMP manufacturing, supporting smoother scale-up and tighter product control.
Read the full article in BioPharm International to explore our platform analytical strategies.
Share article
Related Content